NASDAQ · NARI
Healthcare · Medical - Devices
$79.97
Up+$0.00 (+0.00%)
Updated Oct 12, 2026, 8:47 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NARI
1M range · 0 trading sessions · Daily adjusted prices
NARI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NARI.
Company
Market Activity
Research & News
NARI research
Company profile and research snapshot.
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 8, 2025 | BTIG | Neutral | — |
| Jan 7, 2025 | Wells Fargo | Equal-Weight | — |
| Jan 7, 2025 | Piper Sandler | Neutral | — |
| Jan 7, 2025 | William Blair | Market Perform | — |
| Jan 7, 2025 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
Benzinga · Jan 7, 2025
Stryker Corporation agreed to acquire Inari Medical Inc. for $4.9 billion, expanding its portfolio in the growing venous thromboembolism (VTE) market. The acquisition will strengthen Stryker's peripheral vascular position and provide life-saving solutions for VTE patients.
Benzinga · Jan 6, 2025
Stryker, a global medical technology company, announced a definitive agreement to acquire Inari Medical, a leading provider of solutions for venous thromboembolism. The acquisition will expand Stryker's portfolio and accelerate its impact in endovascular procedures.
Investing.com · Jul 18, 2024
Director William Hoffman of Inari Medical Inc (NARI) sold 60,000 shares, reducing his ownership to 743,296 shares. This sale is part of a broader trend of insider selling at the company, with 33 insider sells and only 2 insider buys in the last year.
Investing.com · Jul 18, 2024
Inari Medical director William Hoffman sold over $3.4 million worth of company stock, reflecting a significant insider transaction. The sales were part of a pre-arranged trading plan, providing insight into the company's performance and the executive's perspective on its valuation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NARI.
No results
No recent SID articles mention NARI.
